Read the Beforeitsnews.com story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Now:
Last hour:
Last 24 hours:
Total:

Imugene has HER-Vaxx Phase 1B Data published in prestigious clinical cancer research journal

% of readers think this story is Fact. Add your two cents.


Imugene Ltd’s (ASX:IMU) (OTCMKTS:IUGNF) Phase 1b clinical trial data for its B cell peptide cancer immunotherapy HER-Vaxx has been published in the prestigious American Association for Cancer Research journal Clinical Cancer Research.

The article – ‘Clinical and immunologic responses to a B-cell epitope vaccine in HER2/neu overexpressing advanced gastric cancer patients – results from Phase 1b trial IMU.ACS.001′ - is authored by Professor Dr Ursula Wiedermann from the Medical University Vienna and study investigators. 

HER-Vaxx well-tolerated and safe 

Induced HER2-specific antibodies and cellular responses were dose-dependent and correlated with clinical responses. 

The highest dose (50 μg) was recommended for further evaluation in a Phase II trial, with chemotherapy + HER-Vaxx or chemotherapy alone, which is currently in its final stages of completion. 

Progression-free survival (PFS) was prolonged in cohort 3, correlating with the vaccine-specific humoral and cellular responses. 

The important clinical endpoint of PFS was met after the statistically significant required number of PFS events has occurred.

Data from these 24 events will now be analysed with the final PFS readout expected within months.

Designed to treat cancerous tumours 

HER-Vaxx is a B-cell peptide cancer immunotherapy designed to treat tumours that over-express the HER-2/neu receptor, such as gastric, breast, ovarian, lung and pancreatic cancers.

The immunotherapy is constructed from several B cell epitopes derived from the extracellular domain of HER- 2/neu.

It has been shown in pre-clinical studies and in Phase 1b and 2 studies to stimulate a potent polyclonal antibody response to HER-2/neu, a well-known and validated cancer target.

Story by ProactiveInvestors


Source: http://www.proactiveinvestors.com/companies/news/947992/imugene-has-her-vaxx-phase-1b-data-published-in-prestigious-clinical-cancer-research-journal-947992.html


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!


Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST

Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST


Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)

Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen!

Nascent Iodine - Promotes detoxification, mental focus and thyroid health.

Smart Meter Cover -  Reduces Smart Meter radiation by 96%! (See Video).

Report abuse

    Comments

    Your Comments
    Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

    MOST RECENT
    Load more ...

    SignUp

    Login

    Newsletter

    Email this story
    Email this story

    If you really want to ban this commenter, please write down the reason:

    If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.